Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.44 |
| ▸ | CHKA | P35790 | 1/20 | 0.43 |
| ▸ | TNKS | O95271 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.39 |
| ▸ | ULK1 | O75385 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 4/20 | 0.39 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KHK | P50053 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3434284 | 0.92 | TNKS (0.49) | ROCK2CHKATNKSTNKS2ULK1 | |
| SCHEMBL21639971 | 0.88 | CHKA (0.44) | CHKANR3C1GSK3BDYRK1ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL21750354 | 0.86 | CHKA (0.43) | CHKANR3C1GSK3BDYRK1ASMN1; SMN2 | |
| SCHEMBL3645472 | 0.84 | CHKA (0.54) | ROCK2CHKADYRK1BNR3C1PBK | |
| SCHEMBL12488082 | 0.75 | CHKA (0.39) | CHKANR3C1SMN1; SMN2 | |
| SCHEMBL16686677 | 0.72 | RAB9A (0.53) | CDK9GSK3B | |
| SCHEMBL22644367 | 0.70 | SMARCA2 (0.50) | ROCK2DYRK1BULK1CDK9JAK2 | |
| SCHEMBL16684845 | 0.70 | ULK1 (0.50) | DYRK1BULK1CDK9JAK2JAK3 | |
| SCHEMBL13326816 | 0.70 | BRD4 (0.39) | CDK9 | |
| SCHEMBL13326812 | 0.70 | BRD4 (0.39) | CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3381913-B1 | 2-(((PYRROLIDIN-3-YL)CARBONYL)AMINO)-1H-IMIDAZOLE DERIVATIVES AS MELANOCORTIN RECEPTOR 1 (MCR1) AGONISTS FOR TREATING RHEUMATOID ARTHRITIS | MITSUBISHI TANABE PHARMA CORP (JP) | 2021-03-31 | — | — | EP | disclosed |
| US-20040259864-A1 | Substituted pyrimidinone derivatives as ligands of integrin receptors | ABBOTT GMBH & CO. KG (DE) | 2004-12-23 | — | — | US | disclosed |
| EP-1362046-A1 | SUBSTITUTED PYRIMIDINONE DERIVATIVES AS LIGANDS OF INTEGRIN RECEPTORS | Abbott GmbH & Co. KG (DE) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002068410-A1 | SUBSTITUTED PYRIMIDINONE DERIVATIVES AS LIGANDS OF INTEGRIN RECEPTORS | ABBOTT GMBH & CO. KG (DE) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259864-A1 | Substituted pyrimidinone derivatives as ligands of integrin receptors | ITGB3, ITGA5, ITGB5 | ROCK2 2519/4885CHKA 2395/4885TNKS 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.